TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06422988

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotics
Description: Any exposure to probiotics in first 14 days of life

Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotics
Description: Any exposure to probiotics in first 14 days of life
Study: NCT05833984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg Q3W IV
Study: NCT04746937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: nitazoxanide adjuvant to standard therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norfloxacin
Description: Standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Standard therapy
Study: NCT05868694

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
Study: NCT04903431

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis Response Planning for Suicide Risk
Description: Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Response Planning for Suicide Risk
Description: Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.
Study: NCT06295172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lafullen15
Description: Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
Study: NCT05924464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Preconception Care
Description: Groups of 6-10 patients to initiate biweekly virtual group care sessions on a rolling basis, with completion of enrollment and the virtual curriculum within a year.
Study: NCT05910580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Description: Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.
Study: NCT06565871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 Injection
Description: Titration administration, SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 Injection
Description: Titration administration, SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: SC
Study: NCT06563661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The 21-style specific dance exercises
Description: The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The 21-style specific dance exercises
Description: The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
Study: NCT05465122

Intervention type: PROCEDURE
Intervention: Carotid Endarterectomy
Description: This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.

Intervention type: PROCEDURE
Intervention: FDA-approved carotid stents
Description: This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.

Intervention type: OTHER
Intervention: Intensive Medical Management
Description: INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.

Intervention type: OTHER
Intervention: Intensive Medical Management
Description: INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.

Intervention type: OTHER
Intervention: Intensive Medical Management
Description: INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.

Intervention type: OTHER
Intervention: Intensive Medical Management
Description: INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
Study: NCT05259696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-602
Description: Subjects will receive E-602 (administered weekly, via IV infusion).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-602
Description: Subjects will receive E-602 (administered weekly, via IV infusion).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-602
Description: Subjects will receive E-602 (administered weekly, via IV infusion).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-602
Description: Subjects will receive E-602 (administered weekly, via IV infusion).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).
Study: NCT06338280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sonara
Description: Sonara virtual dosing window and engagement platform
Study: NCT06149988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC/CBD S.E powder
Description: A single dose of THC/CBD S.E powder- 500 mg, given orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC/CBD oil
Description: Followed by a 30-day washout- A single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
Study: NCT06295172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lafullen
Description: Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
Study: NCT05077033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phIL12 GET
Description: intratumoral phIL12 gene electrotransfer
Study: NCT05694026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light
Description: IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light
Description: IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
Study: NCT06106217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bapne
Description: An exercise program was created in the form of a movement sequence consisting of nine movement combinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: qi gong
Description: The exercise program, which was prepared in a 40-minute sequence, was arranged as 10 minutes of warm-up, 20 minutes of Qi Gong exercises, and 10 minutes of cool-down.
Study: NCT05550259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protocolized postextubation support
Description: The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
Study: NCT05266807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral capsulized Fecal Microbiota Transplantation
Description: FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin or Fidaxomicin
Description: Vancomycin or Fidaxomicin per os as initially prescribed per SoC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin or Fidaxomicin
Description: Vancomycin or Fidaxomicin per os as initially prescribed per SoC
Study: NCT06033963

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
Study: NCT06039293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy and physical activity sessions
Description: The intervention group will receive 10 sessions of cognitive behavioral therapy (CBT) and 6 physical activity sessions over the 12-week period. All Program AACTIVE CBT sessions and exercise sessions will run concurrently and take place virtually using Master of Social Work (MSW) trainees and Movement Science Master of Science students from the University of Michigan.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Usual Care + Diabetes Basics Web Series
Description: Participants will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail.
Study: NCT05375968

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients
Description: While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls
Description: While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2
Description: Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compare change is SVC and SMA flow due to saline
Description: Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
Study: NCT04966117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-Guided DMP
Description: Patients will be assigned a cardiac nurse to help manage their heart condition who will:~1. develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors.~2. provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~3. facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up.~4. invite participation to a supervised 6-week group exercise program which will require using our on-site gym.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.
Study: NCT06569030

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: spinal orthoses
Description: Evaluation of scoliosis treatment in people using spinal orthoses
Study: NCT06377124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3S intervention
Description: The 3S intervention includes information and support related to self-management of lung cancer, including~1. an individual 3S session at baseline,~2. 24-week messaging, telephone coaching and hotline services.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GH information
Description: The GH information includes information related to general health, including~1. an individual GH session at baseline,~2. 24-week messaging, telephone coaching and hotline services.
Study: NCT03105843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine (MCh) Challenge Testing
Description: Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine (MCh) Challenge Testing
Description: Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine (MCh) Challenge Testing
Description: Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Eucapneic Voluntary Hyperventilation (EVH)
Description: Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Eucapneic Voluntary Hyperventilation (EVH)
Description: Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Eucapneic Voluntary Hyperventilation (EVH)
Description: Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol Inhalation Kit
Description: Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol Inhalation Kit
Description: Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol Inhalation Kit
Description: Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
Study: NCT05262361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Office-based Vergence and Accommodative Therapy
Description: Office-based Vergence and Accommodative Therapy has four phases which start with gross vergence and accommodation. Disparity vergence is isolated using instruments such as vectograms and accommodation is isolated using near far charts and accommodative rock. The final phase includes the integration of vergence and accommodation to increase range and visual comfort which performing activities close to the person.
Study: NCT04875104

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment with Invisalign system
Description: Patients are going to receive an orthodontic treatment with Invisalign aligners.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with Spark system
Description: Patients are going to receive an orthodontic treatment with Spark aligners.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with Quicksmile system
Description: Patients are going to receive an orthodontic treatment with Quicksmile aligners.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with ClearCorrect system
Description: Patients are going to receive an orthodontic treatment with ClearCorrect aligners.